Answers are grounded in this paper and cite their sources.
Background: Use of long-term tobramycin inhalation solution (TIS) has been shown beneficial in cystic fibrosis (CF) and earlier findings also suggest a benefit in non-CF bronchiectasis. We investigated the efficacy and safety of maintenance TIS once daily (OD) in frequent exacerbating bronchiectasis patients chronically infected by different pathogens sensitive for tobramycin. Objective: The primary outcome was the frequency of exacerbations during the 12-month study period. Secondary outcomes were time to first exacerbation, change in lung function and quality of life (QoL), bacterial analysis and safety. Materials/patients: In this multicenter RCT patients aged ≥ 18-year-old were included with confirmed bronchiectasis and ≥ 2 exacerbations in the preceding year. Patients were assigned (1:1) to receive TIS or placebo OD for 1-year. Results: 58 patients were included of which 52 were analyzed in the mITT analysis. TIS reduced exacerbation frequency with a RR of 0.74 (0.49-1.14) ( p =0.15). Within the TIS population a significant decrease in number of exacerbations was found (2; p =0.00), which was also seen in the placebo-treated patients (1.5; p =0.00). In the TIS-treated patients the QoL significantly improved (LRTI-VAS p =0.02 Leicester Cough p =0.02) without additional safety concerns. No significant differences were found for the other secondary outcomes. Conclusion: Although the predefined 50% reduction in number of exacerbations was not observed, long-term TIS OD is a safe and effective treatment modality in patients with bronchiectasis chronically infected by tobramycin sensitive pathogens. This could be a useful strategy in selected patients with bronchiectasis suffering from a high burden of disease. The BATTLE study was registered at Clinical trials.gov number: NCT02657473. Date: 13 aug 2016
No takes yet. Share an insight, caveat, or question.
Terpstra et al. (2022) studied this question.